antisense oligonucleotides targeting piRNA-5939

These antisense oligonucleotides (ASOs) are experimental RNA-based therapeutics designed to silence piRNA-5939, a PIWI-interacting RNA that acts as an oncogenic driver in lung adenocarcinoma. The mechanism involves the knockdown of piRNA-5939, which subsequently leads to the downregulation of PIWIL3 mRNA and protein levels. This suppression inhibits key oncogenic signaling pathways related to the cell cycle, cytoskeletal remodeling, and RNA stability. In preclinical models, treatment with these ASOs has demonstrated a significant reduction in lung cancer cell proliferation (approximately 40%) and migration (approximately 55%), suggesting that the piRNA-5939/PIWIL3 axis is a viable therapeutic target for lung cancer.

Other names

piRNA-5939 ASOspiRNA5939 ASOspiRNA 5939 ASOspiRNA-5939 inhibitorspiRNA5939 inhibitorspiRNA 5939 inhibitors